Tryptamine prodrugs
US11292765B2 · kind B2 · utility
13Cited by
1References
23Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 30, 2021 |
| Grant date | Apr 5, 2022 |
| Priority date | — |
| Expiry date | Jun 30, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.